NGNE at a glance
Neurogene Inc. (NGNE, SEC CIK 1404644) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Neurogene Inc. (NGNE) shares worth $109.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cvijic Christine Mikail on July 7, 2026 of 4,200 shares at $36.13 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $109.5M · +3 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No commercial revenue; net loss $65.4M for six months ended June 30, 2026 vs $44.7M YoY
- Cash, equivalents and short-term investments $225.4M at June 30, 2026
- July 2, 2026 public offering generated $134.8M net proceeds
- Cash runway expected into first quarter of 2029 following offering
- Top-line Embolden trial results expected second half of 2027; macroeconomic and supply-chain risks remain
Risk Factors
- Newly triggered program risk: FDA denial of NGN-101’s RMAT designation precludes the streamlined registrational pathway, forcing program reevaluation
- Most materially updated clinical risk: NGN-401 Embolden trial dosing completed in the second quarter of 2026, but regulatory approval remains uncertain
- Regulatory risk: Gene therapy approval requirements remain rigorous, complex, uncertain and subject to change
- Operational risk: NGN-401 dependence concentrates near-term execution on the company’s lead program
- Financial risk: Cumulative net loss reached $418.1 million through June 30, 2026, with cash expected to fund operations into the first quarter of 2029
AI summary of the NGNE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exhibits 99.1 and 99.2 furnished under Item 2.02, likely containing the earnings disclosure
- Materials not deemed filed under Exchange Act Section 18, limiting liability exposure
Item 8.01: Other Events
- Offering proceeds extend Neurogene’s funding runway through the first quarter of 2029
- Combined liquidity expected to cover operating expenses and capital expenditures
Item 1.01: Entry into a Material Definitive Agreement
- $134.8M expected net proceeds from equity offering, strengthening Neurogene’s cash position
- 3.5M common shares sold at $30.00 plus pre-funded warrants for 666,666 shares
Item 8.01: Other Events
- Positive updated Phase 1/2 clinical data for NGN-401 Rett syndrome gene therapy
- Data cover females with Rett syndrome, supporting continued clinical development
Item 7.01: Regulation FD Disclosure
- Updated positive Phase 1/2 NGN-401 data for females with Rett syndrome, potentially strengthening clinical and commercial prospects
- Results discussed June 29, 2026 conference call and webcast
AI summaries of NGNE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NGNE
Don't miss the next NGNE filing
- Alerts as it files. A push when NGNE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NGNE, by share count.
- Ask anything. An AI agent that reads every NGNE filing and answers with sources.
NGNE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McMinn Rachel | M | Sep 22, 2026 | 756 | - |
| McMinn Rachel | M | Sep 22, 2026 | 756 | $25.32 |
| Cvijic Christine Mikail | Sell | Jul 7, 2026 | 4,200 | $36.13 |
| Cvijic Christine Mikail | Sell | Jul 6, 2026 | 600 | $36.02 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 1,530 | $35.23 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 2,531 | $34.58 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 1,530 | $35.23 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 2,531 | $34.58 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $925K | $0 |
| Operating Income | -$55.6M | -$82.6M | -$103.3M |
| Net Income | - | -$75.1M | -$90.4M |
| Op. Margin | - | -8930.3% | - |
| Net Margin | - | -8123.7% | - |
| Balance Sheet | |||
| Total Assets | - | $335.7M | $288.6M |
| Equity | - | $310.4M | $264.9M |
| ROE | - | -24.2% | -34.1% |
| Per Share | |||
| EPS | $2.93 | $-4.28 | $-4.24 |
| Cash Flow | |||
| Operating CF | -$51.4M | -$70.6M | -$77.2M |
| CapEx | $321K | $808K | $1.2M |
Source: XBRL data in Neurogene Inc. (NGNE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NGNE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $109.5M |
| Q1 2026 | 21 | $71.6M |
| Q4 2025 | 20 | $67.1M |
| Q3 2025 | 16 | $49.0M |
| Q2 2025 | 17 | $50.7M |
| Q1 2025 | 15 | $25.0M |
| Q4 2024 | 11 | $43.2M |
| Q3 2024 | 9 | $23.7M |
- BlackRock+52.9K (+5%)
- Vanguard Portfolio Management LLC+30.5K (+47%)
- Citadel Advisors LLC+22.0K (+6%)
- Vanguard Capital Management LLC+21.8K (+4%)
- Dimensional Fund Advisors+21.2K (+186%)
- Millennium Management−162.1K (-79%)
- Morgan Stanley−93.5K (-33%)
- State Street Corp−88.7K (-28%)
- FMR LLC (Fidelity)−87.1K (-23%)
- Renaissance Technologies LLC−23.0K (-53%)
- Franklin Resources+204.3K
- D.E. Shaw & Co+9.8K
- T. Rowe Price Group+8.9K
- Invesco Ltd+6.7K
- Two Sigma Investments−13.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NGNE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 8-K | Apr 20, 2026 | - | Analysis | - |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NGNE SEC filings: frequently asked questions
Which institutions hold NGNE stock?
As of June 30, 2026, the largest Neurogene Inc. (NGNE) holders among the 13F filers tracked by SignalX were BlackRock ($33.3 million), Vanguard Capital Management LLC ($16.9 million), Citadel Advisors LLC ($12.9 million), FMR LLC (Fidelity) ($9.3 million), State Street Corp ($7.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NGNE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24. The figures come from the XBRL data in the 10-K.
What did NGNE report in its latest 8-K?
Neurogene Inc. (NGNE) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibits 99.1 and 99.2 furnished under Item 2.02, likely containing the earnings disclosure.
What are the latest NGNE SEC filings?
Neurogene Inc. (NGNE) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on October 2, 2026.
What is NGNE's SEC CIK number?
Neurogene Inc. (NGNE)'s SEC Central Index Key (CIK) is 1404644. EDGAR lists every NGNE filing under that number.
Ask anything about NGNE
The research agent reads NGNE's filings, financials, insider trades and 13F holders, then answers with sources.